PIGINI, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.568
EU - Europa 4.474
AS - Asia 3.833
SA - Sud America 428
Continente sconosciuto - Info sul continente non disponibili 239
AF - Africa 141
OC - Oceania 25
Totale 19.708
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.202
CN - Cina 1.739
SG - Singapore 1.057
RU - Federazione Russa 1.020
DE - Germania 931
IT - Italia 631
BR - Brasile 359
UA - Ucraina 310
CA - Canada 305
GB - Regno Unito 296
VN - Vietnam 284
SE - Svezia 277
FI - Finlandia 264
HK - Hong Kong 257
FR - Francia 251
PL - Polonia 202
TR - Turchia 118
ZA - Sudafrica 103
KR - Corea 98
IN - India 70
IE - Irlanda 69
BD - Bangladesh 51
CZ - Repubblica Ceca 51
BE - Belgio 45
MX - Messico 39
EU - Europa 35
JP - Giappone 34
NL - Olanda 29
AR - Argentina 28
IR - Iran 26
AU - Australia 23
ES - Italia 23
LT - Lituania 17
EC - Ecuador 15
IQ - Iraq 14
RO - Romania 13
PK - Pakistan 12
EG - Egitto 11
ID - Indonesia 10
CO - Colombia 9
MA - Marocco 8
RS - Serbia 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
CH - Svizzera 6
DZ - Algeria 6
JM - Giamaica 6
NP - Nepal 6
PH - Filippine 6
JO - Giordania 5
KE - Kenya 5
SA - Arabia Saudita 5
TW - Taiwan 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BG - Bulgaria 4
CL - Cile 4
HU - Ungheria 4
IL - Israele 4
NI - Nicaragua 4
PE - Perù 4
VE - Venezuela 4
AL - Albania 3
AZ - Azerbaigian 3
GR - Grecia 3
HN - Honduras 3
KH - Cambogia 3
MY - Malesia 3
PA - Panama 3
PY - Paraguay 3
SN - Senegal 3
BY - Bielorussia 2
DK - Danimarca 2
GT - Guatemala 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AD - Andorra 1
AM - Armenia 1
BH - Bahrain 1
BO - Bolivia 1
BZ - Belize 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
LB - Libano 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
MT - Malta 1
MU - Mauritius 1
NG - Nigeria 1
Totale 19.504
Salva come PNG Salva come JPEG
Città #
Dallas 968
Woodbridge 773
Jacksonville 746
Ashburn 722
Chandler 606
Singapore 594
Fairfield 574
Ann Arbor 503
San Jose 402
Wilmington 383
Houston 380
Council Bluffs 344
Beijing 296
Boardman 287
Nanjing 258
Hong Kong 248
Seattle 235
Cambridge 188
Toronto 186
Los Angeles 170
Dearborn 169
The Dalles 155
Düsseldorf 139
New York 131
Kraków 123
Helsinki 119
San Mateo 117
Ho Chi Minh City 103
Columbus 98
Nanchang 98
Seoul 96
Johannesburg 95
Lawrence 93
Princeton 93
Tongling 93
Lauterbourg 90
Istanbul 87
Buffalo 75
Munich 74
Warsaw 74
Ogden 71
Dublin 68
Lachine 67
Moscow 66
Santa Clara 64
London 61
Shanghai 60
Shenyang 59
Camerino 57
Kunming 57
Orem 57
Hanoi 56
Tianjin 55
Guangzhou 51
São Paulo 46
Brussels 45
Venezia 44
Turku 43
Milan 42
Changsha 41
Jiaxing 41
Brno 40
Hebei 37
Chicago 35
Jinan 33
Hangzhou 32
Nürnberg 32
Chennai 31
San Diego 29
Tokyo 28
Denver 27
Philadelphia 27
Venice 26
Washington 26
Zhengzhou 26
Poplar 25
Falls Church 24
Phoenix 23
Frankfurt am Main 21
Montreal 20
Wuhan 20
Boston 19
Brooklyn 19
Orange 19
Redwood City 19
Da Nang 17
Manchester 17
Mexico City 17
Taizhou 17
Fuzhou 16
Amsterdam 15
Leawood 15
Ningbo 15
Stockholm 15
Verona 15
Atlanta 14
Monmouth Junction 14
Old Bridge 14
Hefei 13
Ankara 12
Totale 13.000
Salva come PNG Salva come JPEG
Nome #
1,4-DIOXANE NUCLEUS AS A SUITABLE SCAFFOLD FOR NOVEL D2-LIKE RECEPTOR LIGANDS 632
1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists 629
1,4-Dioxane ring as a promising template of novel 5-HT1A full agonists 564
1'-Benzyl-3,4-dihydrospiro[2H-1-benzothiopyran-2,4'-piperidine] (Spipethiane), a potent and highly selective sigma1 lingand 558
Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation 344
The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A Receptor 336
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 330
Hyperphagic effect of novel compounds with high affinity for imidazoline I2 binding sites 307
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 303
Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction 294
Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions 271
2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors 266
Investigation of allyphenyline efficacy in the treatment of alcohol withdrawal symptoms 258
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement. 254
Biological profile and bioavailability of imidazoline compounds on morphine tolerance modulation 245
alpha(2)-Adrenoreceptors profile modulation. 2. Biphenyline analogues as tools for selective activation of the alpha2C-subtype 240
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 239
Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors 230
Imidazoline binding sites (IBS) profile modulation: Key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues 228
Discovery of Highly Selective Imidazoline Receptor Ligands 227
Novel 1,4-dioxane derivatives as NMDA receptor channel blockers 224
Structure-activity relationships in 1,4-benzodioxan-related compounds. Investigation on the role of the dehydrodioxane ring on alpha1-adrenoreceptor blocking activity 222
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 221
Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane 218
Structure−Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11.1 Reversed Enantioselectivity of 1,4-Dioxane Derivatives in α1‑Adrenergic and 5‑HT1A Receptor Binding Sites Recognition 217
3-Phenyl analogues of 2-[[[2-(2,6-Dimethoxyphenoxyethyllamino]methyl]-1,4-benzodioxan (WB 4101) as highly selective alpha1-adrenoreceptor antagonists1 215
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 214
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 213
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 213
Novel Imidazoline Compounds as Partial or Full Agonists of D2-Like Dopamine Receptors Inspired by I2-Imidazoline Binding Sites Ligand 2-BFI 211
Synthesis and muscarinic properties of (1S*,3R*,5R*)-trimethyl(1-methyl-6-oxabicyclo[3.1.0]hex-3-yl)methyl ammonium iodide 211
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 208
Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit an antidepressant-like effect 208
Homoazanicotine: A structure-affinity study for nicotinic acetylcholine (nACh) receptor binding 207
Might Adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine? 207
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 205
Alpha(2)-Adrenoreceptors Profile Modulation. 3. (R)-(+)-m-Nitrobiphenyline, a New Efficient and alpha(2C)-Subtype Selective Agonist. 204
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation 203
Use of frozen sections for the pharmacological characterization of compounds active on neurotransmitter receptors 202
28th Camerino-Cyprus-Noordwijkerhout Symposium - Trekking through Receptor Chemistry 201
Novel Dopamine Receptor Ligands Bearing Imidazoline Nucleus. 197
Enantioselective interactions to improve adrenergic α2C-agonism/α2A-antagonism 196
Potent muscarinic antagonists bearing 1,4-dioxane scaffold 195
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity 194
“Pharmacological Characterization of Muscarinic Receptor Subtypes in Rabbit Isolated Tissue Preparations” 193
Chain-lengthened and imidazoline analogues of nicotine 192
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 192
Muscarinic Thioligands with Cyclopentane Nucleus 192
Allyphenyline analogues potentially useful in the management of chronic pain and opioid addiction. 191
NOVEL BIVALENT LIGANDS OF XANOMELINE AND 77-LH-28-1 AS POTENTIAL M1 MUSCARINIC AGONISTS 189
Synthesis and Structure-Activity Relationship Studies in a Series of 2-Substituted 1,3-Dioxolanes Modified at the Cationic Head. 185
Age-related Changes in the Density of Muscarinic Cholinergic M1 and M2 Receptor Subtypes in Pyramidal Neurons or the rat Hippocampus 185
Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models 185
Fruitful Adrenergic alpha(2C)-Agonism/alpha(2A)-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence 184
Synthesis, Absolute Configuration, and Biological Profile of the Enantiomers of trans-[2-(2,6-Dimethoxypheoxy)ethyl] [(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (Mephendioxan), a Potent Competitive alpha 1A-Adrenoreceptor Antagonist 183
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4 chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation 181
Agonists and antagonists targeting the different alpha(2)-adrenoceptor subtypes 180
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 180
Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity 178
Dual Alpha2C/5HT1A Receptor Agonist Allyphenyline Induces Gastroprotection and Inhibits Fundic and Colonic Contractility 177
Pharmacophore development and 3D-QSAR study of I1 imidazoline binding site ligands 176
alpha(2)-adrenoreceptors profile modulation. 4. From antagonist, to agonist behavior 176
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9.From 1,4-benzodioxan to 1,4-dioxane ring as a promising template of novel alpha(1D)-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents. 175
MORPHINE TOLERANCE MODULATION INDUCED BY alpha2-ADRENERGIC OR/AND I2 IMIDAZOLINE BINDING SITES LIGANDS 174
Rational design of novel I1-imidazoline receptor agonists 173
Might adrenergic α2C-agonist/α2A-antagonist become a novel therapeutic multitarget tool for morphine chronic treatment of pain? 172
Adrenoceptors as targets in drug discovery: Medicinal chemistry and therapeutical potential 169
Imidazoline nucleus as a biologically versatile scaffold 168
Byciclic dioxolanes as potential antimuscarinic agents 167
From benzodioxane to 1,4-dioxane scaffold in the design of 5-HT1A serotoninergic full agonists from α1-adrenergic antagonists 166
I1 imidazoline receptor-mediated effects on apoptotic processes in PC12 cells. 166
Effects of allyphenyline on chronic alcohol intoxication model 162
Alpha 1-adrenoreceptor antagonists bearing a quinazoline or a benzodioxane moiety 160
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 4. Effect of aryl and alkyl Substituents at Position 3 on α-adrenoreceptor blocking activity 160
Hybrid molecules from xanomeline and 77-LH-28-1 as potential novel M1 muscarinic agonists 159
Rational design of new alpha(2)-adrenoreceptor agonists 158
Structure-activity relationship at alpha-adrenergic receptors within a series of imidazoline analogues of cirazoline 156
Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 6. Role of the Dioxane Unit on Selectivity for Alpha1-Adrenoreceptor Subtypes 146
Binding of Tracizolines to the Imidazoline Receptor. Role of Lipophilicity in Quantitative Structure-Activity Relationship Models. 146
Molecular determinants in the binding of novel 1,4-benzodioxan-related α1D-adrenergic receptor antagonists: a computational study 145
Novel muscarinic antagonists designed on the 1,4-dioxane scaffold 141
Separation of alpha-adrenergic and imidazoline/guanidinium receptive sites (IGRS) activity in a series of imidazoline analogues of cirazoline 141
Enantiomers of 6,6-diphenyl-1,4-dioxane derivatives to highlight stereochemical requirements for selective alpha1D-AR and 5- HT1A receptor recognition 140
Structural motives of imidazoline molecules favouring the serotonin 5-HT1A receptor activation 137
Copresence of 1,4-dioxane and quinuclidine nuclei in the design of novel muscarinic antagonists 136
Structure-activity relationships in 1,4-benzodioxan-related compounds. 10. Novel alpha1-adrenoreceptor antagonists related to openphendioxan: synthesis, biological evaluation, and alpha1d computational study 135
Might the observed alpha2A-adrenoreceptor agonism or antagonism of allyphenyline analogues be ascribed to different molecular conformations? 133
Structure- Activity Relationships in 1,4-Benzodioxan-related Compounds. 5. Effects of Modification of the side chain on alpha-adrenoreceptor blocking Activity 129
Novel α1-adrenoreceptor antagonists related to openphendioxan: biological evaluation and α1d computational study 126
Synthesis and alpha-blocking activity of some analogues of idazoxan 126
Coupling of I-1 Imidazoline Receptors to the cAMP Pathway: Studies with a Highly Selective Ligand, Benazoline 124
Synergic stimulation of serotonin 5-HT1A receptor and α2-adrenoceptors for neuropathic pain relief: Preclinical effects of 2-substituted imidazoline derivatives 123
Alpha2C-adrenoceptor modulators: a patent review 115
Totale 19.708
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.159
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.159
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022928 0 241 15 74 66 61 25 75 74 118 63 116
2022/20231.528 176 54 66 238 172 204 10 102 284 87 85 50
2023/2024967 156 61 66 28 41 85 34 15 100 37 23 321
2024/20253.009 118 78 250 136 74 156 377 719 246 187 203 465
2025/20265.147 289 353 1.083 667 524 387 692 282 246 248 207 169
2026/2027347 245 102 0 0 0 0 0 0 0 0 0 0
Totale 19.708